Solid execution and cost disciplinePoised for next phase of Transformational JourneyThird Quarter 2024 Financial Highlights:Net Revenues of ...

Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Hello. Greetings and welcome to the YPF Third Quarter 2024 Earnings Webcast Presentation. All participants are in a listen-only mode at this ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Inseego has been unprofitable for two decades, struggling to operate beyond its breakeven level despite being in a growth ...

Research and development expenses increased to $17.0 million for the three months ended September 30, 2024 from $15.4 million for the three months ended September 30, 2023 primarily due to ...

Perfect for special occasions or as a thoughtful gift, Loubier's design ... family operated company, involves small batches ...

Pharmacokinetic Results: TX45 demonstrated a potential best-in-class half-life for a long-acting relaxin therapy. Final analysis showed that a single dose of TX45 had approximately 50% subcutaneous ...

Operator: Good morning. My name is Ludy, and I will be your conference operator today. At this time, I would like to welcome ...